created by
robolab.io
PDA Technical Report No. 82 (TR 82), titled was published in March 2019 to provide critical guidance on the phenomenon of Low Endotoxin Recovery (LER).
The industry was thrown into a "hotly-contested" debate about how to handle this mystery. To provide a roadmap, the Parenteral Drug Association (PDA) formed a task force of experts from the , academia, and the pharmaceutical industry. After three years of intensive work, they published Technical Report No. 82 (TR 82)
: TR 82 includes 12 real-world case studies from biologics manufacturers that detail root-cause analyses and successful methodologies for overcoming LER. Regulatory Importance pda technical report 82
: The report outlines how to design and perform hold-time studies to determine if a drug product’s matrix causes endotoxin masking.
Since its release, TR 82 has become a recognized standard by major health authorities, including the EMA. However, as of 2024–2025, there are ongoing industry efforts and PDA conferences focused on revising the report to address new data on the clinical relevance of LER and the effectiveness of different endotoxin types. Technical Report No. 82 "Low Endotoxin Recovery" PDA Technical Report No
Before implementing, a formal risk assessment (e.g., FMEA – Failure Mode and Effects Analysis) must be conducted to identify potential failure points, such as cold spots, dead legs, or pump overheating due to low flow.
LER is defined as the inability to recover over time when a known amount of endotoxin is added to an undiluted product. It is particularly common in biologics containing a combination of chelators (like citrate or phosphate) and surfactants (like polysorbate). Core Guidance in TR82 To provide a roadmap, the Parenteral Drug Association
The report provides guidance on conducting "hold time studies," which involve: